NLRP3 and neoplasm: Pharmacological inhibition of NLRP3 inflammasome using MCC950, followed by PTX administration decreased the pro-inflammatory processes associated with anti-tumor treatment as indicated by the expression of NLRP3, caspase-1, IL-1β and IL-18, compared with PTX treatment.